Management of hyperlipidemia among patients with rheumatoid arthritis in the primary care setting
Open Access
- 3 September 2015
- journal article
- research article
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 16 (1) , 237
Abstract
Rheumatoid arthritis (RA) has been associated with an increased risk of cardiovascular morbidity and mortality but this has not translated to optimal management of traditional cardiovascular risk factors such as hyperlipidemia. The objectives of this study were to 1) determine the prevalence of screening for hyperlipidemia in patients with RA followed by primary care practitioners (PCP); 2) examine initiation of lipid-lowering therapy in patients with an indication, and 3) assess whether proposed modifications to cardiovascular risk calculations change the percentage of RA patients with an indication for therapy. We performed a retrospective cohort study using an academic medical center-based medical record database in the United States. Patients with RA defined by the presence of at least one ICD-9 code between 2005–2010 and followed by a PCP within the health care system were included. The positive predictive value of ICD-9 codes for accurately identifying patients with RA was 96.7 %. Descriptive statistics were used to report the prevalence of screening and use of lipid-lowering therapy among those with an indication. Factors associated with not receiving lipid screening were examined using logistic regression models. Indication for and receipt of therapy were then assessed before and after the application of the European Union League Against Rheumatism (EULAR) recommended multiplier to the Framingham risk score. Among 1,056 patients with RA followed by PCPs and eligible for lipid screening, lipid screening was ordered for 539 (51 %) within the 3-year follow-up period. Patients with diabetes, hypertension, chronic kidney disease, obesity or age >50 were more likely to be screened. Of those with lipid results (N = 290), 25 (9 %) patients had an indication for lipid-lowering therapy based on Adult Treatment Panel III guidelines. Ten (40 %) patients with an indication for lipid-lowering therapy received therapy did not receive therapy. Applying the EULAR multiplier only changed the indication for lipid-lowering therapy in two patients. Screening and management of traditional cardiovascular risk factors, including hyperlipidemia, need to be optimized.Keywords
This publication has 30 references indexed in Scilit:
- Usefulness of Risk Scores to Estimate the Risk of Cardiovascular Disease in Patients With Rheumatoid ArthritisThe American Journal of Cardiology, 2012
- Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: A population‐based studyArthritis Care & Research, 2012
- Use of disease‐modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care SurveyArthritis Care & Research, 2011
- Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort studyAnnals of the Rheumatic Diseases, 2011
- Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care PlansJAMA, 2011
- Low frequency of primary lipid screening among Medicare patients with rheumatoid arthritisArthritis & Rheumatism, 2011
- Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?Annals of the Rheumatic Diseases, 2010
- EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritisAnnals of the Rheumatic Diseases, 2010
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) StatementEpidemiology, 2007
- Patterns of cardiovascular risk in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006